Duyuru • Jul 07
Verici Dx plc to Report Fiscal Year 2025 Results on Jul 08, 2026 Verici Dx plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Jul 08, 2026 Duyuru • Jun 29
Verici Dx plc, Annual General Meeting, Jul 28, 2026 Verici Dx plc, Annual General Meeting, Jul 28, 2026. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom Duyuru • Jun 25
Verici Dx Receives New York State Approval for Tutivia Kidney Transplant Rejection Test Verici Dx plc received clinical laboratory accreditation from the New York State Department of Health Clinical Laboratory Evaluation Program. The Company also received New York state approval of Tutivia, its blood-based laboratory developed test that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant. By detecting rejection-associated biological mechanisms, the Tutivia test provides clinicians with a proactive indicator of rejection risk, enabling more precise patient management and risk stratification, better-timed interventions, and the potential to reduce avoidable biopsies and graft loss. With this New York state certification, Verici Dx is now authorized to provide laboratory testing services in all 50 U.S. states and the District of Columbia, creating nationwide availability of the Tutivia test. Tutivia combines transcriptomics with proprietary machine learning algorithm to deliver predictive intelligence for acute kidney transplant rejection. The test provides clinicians with deeper insight to support more precise immunosuppression management by distinguishing rejection from other causes of graft injury, such as BK virus–associated nephropathy and ischemia–reperfusion injury, which can confound conventional blood tests including serum creatinine and cell-free DNA. The science underlying Tutivia was pioneered at The Mount Sinai Hospital in New York. Its development is grounded in decades of clinical expertise and scientific rigor, and New York State approval represents a full-circle milestone, bringing a locally developed innovation back to the state’s transplant community with nationwide reach. The Tutivia test was validated in a clinical study that included a broad and diverse transplant patient population. Duyuru • Jun 24
Verici Dx plc Receives New York State Clinical Laboratory Certification Verici Dx Plc, a developer of advanced clinical diagnostics for organ transplant, announced that it has received clinical laboratory certification from the New York State Department of Health Clinical Laboratory Evaluation Program. Having achieved New York state certification, the nation's most rigorous laboratory evaluation program, Verici Dx has now completed its full authorisation to provide laboratory testing services in all 50 US states and the District of Columbia, creating nationwide availability of the Tutivia test. The Company also received state approval for Tutivia, its blood-based laboratory developed test that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant. Duyuru • Jun 12
Verici Dx plc has completed a Follow-on Equity Offering in the amount of AUD 0.18671 million. Verici Dx plc has completed a Follow-on Equity Offering in the amount of AUD 0.18671 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 53,345,832
Price\Range: AUD 0.0035 Duyuru • Jun 10
Verici Dx plc has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Verici Dx plc has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 57,142,857
Price\Range: AUD 0.0035 Duyuru • May 20
Verici Dx plc Announces Publication Validating Pre-Transplant Gene Signature Test For Predicting Early Acute Rejection In Kidney Transplant Recipients Verici Dx plc announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific. The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features. PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant. Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy. Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade. The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test. Duyuru • Apr 18
Verici Dx plc Appoints Keith Gilliard as Senior Director of Sales Verici Dx plc announced that Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals. Duyuru • Oct 08
Verici Dx plc Announces Board Changes, Effective October 6, 2025 Verici Dx plc announced the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect. Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations. Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance. Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals. In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship: Aubrey Powell Consulting (APC) Limited. Previous directorships or partnerships of which the director has been a director or partner over the last five years: Apus Sequestration LLP and Maia Green LLP. Mr. Powell holds no shares in the Company. Duyuru • Jul 29
Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million. Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million.
Security Name: Ordinary shares
Security Type: Common Stock
Securities Offered: 86,286,792
Price\Range: £0.005 Duyuru • Jul 21
Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million. Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,000,000,000
Price\Range: £0.005
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,439,092
Price\Range: £0.005
Transaction Features: Regulation S; Subsequent Direct Listing Duyuru • Jun 30
Verici Dx plc, Annual General Meeting, Jul 29, 2025 Verici Dx plc, Annual General Meeting, Jul 29, 2025. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom Duyuru • Apr 08
Verici Dx plc Provides Earnings Guidance for the Year 2024 Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million. Duyuru • Jul 12
Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024 Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024 Duyuru • Jun 08
Verici Dx plc, Annual General Meeting, Jun 25, 2024 Verici Dx plc, Annual General Meeting, Jun 25, 2024. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom Duyuru • Feb 14
Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million. Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 69,111,111
Price\Range: £0.09
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,111,111
Price\Range: £0.09
Transaction Features: Regulation S; Subsequent Direct Listing Duyuru • Jan 24
Verici Dx plc, Annual General Meeting, Feb 19, 2024 Verici Dx plc, Annual General Meeting, Feb 19, 2024, at 12:00 Coordinated Universal Time. Location: the offices of Shoosmiths London at No. 1 Bow Churchyard London United Kingdom Agenda: To approve the total number of new Ordinary Shares to be issued pursuant to the Fundraising and Admission. Duyuru • Jan 08
Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024 Verici Dx plc announced that the Centers for Medicare & Medicaid Services released the Clinical Laboratory Fee Schedule payment rate of $2,650 established through the "gapfill" process for both Tutiviatm (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Claravatm (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024. Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors. Duyuru • Jul 22
Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 States Verici Dx plc announced that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California, with the Company laboratory now fully accredited in a total of 49 states. Together with the CLIA certification previously obtained from the Centers for Medicare & Medicaid ("CMS"), clinicians at transplant medical centres in these additional states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach. California has consistently accounted for over 10% of the national US volume of kidney transplant procedures in each year since 1998 and has conducted the highest volume of transplants by any state each year over the same period. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the successful validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year. The additional state accreditations provide further validation of Verici Dx's clinical laboratory for its tests to be used by transplant clinicians across the US. The Company continues to work towards full accreditation in the final state of New York, which has its own compliance requirements. The CLIA certification and additional state approvals further exemplify Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostic services to clinicians and patients in need. Duyuru • Jul 04
Verici Dx plc Announces Successful Validation Results from Its Prospective, Blinded, International Multi-Centre Clinical Validation Study for Clarava Verici Dx plc announced successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™?. Clarava™?, is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™? as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis. Verici Dx is on track to commence the initial US commercial launch of Clarava™? before the end of 2023. The Company has received a preliminary Medicare gapfill median rate of $2,650 for Clarava™? from the Centers for Medicare & Medicaid Services. The Clarava™ study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava™ demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava™ as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava™ in conjunction with our post-transplant test, Tutivia™. Clarava™ is the only pre-transplant test of its kind that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardized and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As reported, the Clarava™ personalized risk assessment is especially important for the expanding DD transplant population. Duyuru • Jun 06
Verici Dx plc, Annual General Meeting, Jun 29, 2023 Verici Dx plc, Annual General Meeting, Jun 29, 2023, at 13:00 Coordinated Universal Time. Location: Avon House, 19 Stanwell Road, Penarth, Cardiff Wales United Kingdom Duyuru • May 31
Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023 Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023